Repare Therapeutics Inc · Q3 2024 earnings

Briefing

Repare Therapeutics reported financial results for the third quarter ended September 30, 2024 and provided a business and clinical update.

Repare Therapeutics reported a net loss of $34.4 million, or $0.81 per share, for the third quarter ended September 30, 2024. The company's cash, cash equivalents, and marketable securities totaled $179.4 million as of September 30, 2024, expected to fund operations into the second half of 2026. Advances were made across the pipeline, including dosing the first patient in the POLAR clinical trial and presenting clinical benefits of camonsertib in combination with radiotherapy.

• On track to report data from the ongoing MYTHIC dose expansion clinical trial at the RP2D at a company event in December 2024, with the plan to begin a registrational trial in 2025.
• Presented updated positive safety and tolerability results from the Phase 1 MYTHIC clinical trial at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
• Dosed first patient in Phase 1 POLAR trial evaluating RP-3467, a Polq ATPase inhibitor, alone and in combination with the PARP inhibitor, olaparib.
• Presented first-in-human data highlighting the clinical benefits of camonsertib in combination with radiotherapy at the ASTRO annual meeting.

Headline financials

Revenue & EPS history

The Company believes that its cash, cash equivalents, and marketable securities are sufficient to fund its current operational plans into the second half of 2026.